From the Guidelines
Arnuity Ellipta (fluticasone furoate) is recommended at a dose of 50 mcg once daily for pediatric patients aged 5-11 years, and 100-200 mcg once daily for adolescents aged 12-17 years. The medication should be administered as one inhalation once daily at the same time each day. For children with more severe asthma or those who have inadequate control on the lower dose, the higher dose within the appropriate age range may be considered. The medication works as an inhaled corticosteroid that reduces airway inflammation, decreases bronchial hyperresponsiveness, and helps control asthma symptoms. Some key points to consider when prescribing Arnuity Ellipta include:
- Ensuring proper inhalation technique to maximize the medication's effectiveness
- Rinsing the mouth after use to prevent oral thrush
- Using the medication regularly, even when the child is asymptomatic, to maintain asthma control
- Monitoring for potential side effects, such as reduced linear growth rate in children, and adjusting the dose as needed to minimize risks Improvement in symptoms may begin within 24 hours, though maximum benefit may take 1-2 weeks 1. It's essential to weigh the benefits of inhaled corticosteroid therapy against the potential risks, particularly at higher doses, and to consider adjunctive therapies for patients with poorly controlled asthma. Key considerations for pediatric patients include:
- Starting with a low dose and titrating up as needed to minimize the risk of systemic effects
- Monitoring growth and development in children taking inhaled corticosteroids long-term
- Educating parents and caregivers on proper medication use and potential side effects.
From the Research
Recommended Dose of Arnuity Ellipta for Pediatric Patients
- The recommended dose of Arnuity Ellipta (fluticasone furoate) for pediatric patients is not explicitly stated in the provided studies 2, 3, 4, 5, 6.
- However, it is worth noting that the studies primarily focus on adult patients with asthma, and there is limited information available on the use of Arnuity Ellipta in pediatric patients.
- Study 2 mentions that the study included patients aged ≥ 12 years, but it does not provide specific dosing recommendations for pediatric patients.
- The other studies 3, 4, 5, 6 do not mention pediatric patients or provide dosing recommendations for this population.
Available Information on Arnuity Ellipta
- Arnuity Ellipta is a once-daily inhaled corticosteroid (ICS) used for the treatment of asthma 2, 3, 4, 5, 6.
- The studies provide information on the efficacy and safety of Arnuity Ellipta in adult patients with asthma, but there is a lack of data on its use in pediatric patients.
- Further studies are needed to determine the recommended dose of Arnuity Ellipta for pediatric patients and to assess its safety and efficacy in this population.